Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
INTERPACE BIOSCIENCES INC (IDXG)
Last interpace biosciences inc earnings: 11/13 04:40 pm
Check Earnings Report
US:NASDAQ Investor Relations:
interpacediagnostics.com/investors
Company Research
Source: GlobeNewswire
Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net Income and EBITDA operations Company to seek uplisting on the Nasdaq Stock Market PARSIPPANY, NJ, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (OTCID: IDXG) (“Interpace” or the “Company”) today announced preliminary and unaudited 2025 revenue from continuing operations (i.e., thyroid testing), initial 2026 revenue guidance, and updates on the Company’s capital structure and plans to seek an uplisting on The Nasdaq Stock Market. Preliminary 2025 Revenue Interpace announced preliminary and unaudited revenue of approximately $38-39 million in 2025. Thyroid testing represented approximately $34-35 million in revenue. This represents growth of approximately 21% in thyroid testing revenue over 2024. As announced previously, the Company’s PancraGEN test
Show less
Read more
Impact Snapshot
Event Time:
IDXG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IDXG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IDXG alerts
High impacting INTERPACE BIOSCIENCES INC news events
Weekly update
A roundup of the hottest topics
IDXG
News
- Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital Partners [Yahoo! Finance]Yahoo! Finance
- Interpace Biosciences Announces Early Repayment of Debt to BroadOak Capital PartnersGlobeNewswire
- Interpace Biosciences GAAP EPS of $0.04, revenue of $8.76M [Seeking Alpha]Seeking Alpha
- Interpace Biosciences Announces Third Quarter 2025 Financial and Business Results [Yahoo! Finance]Yahoo! Finance
- Interpace Biosciences Announces Third Quarter 2025 Financial and Business ResultsGlobeNewswire
IDXG
Sec Filings
- 1/20/26 - Form 8-K
- 12/3/25 - Form 8-K
- 11/12/25 - Form 8-K
- IDXG's page on the SEC website